First, do no harm.
作者信息
Pimlott Nicholas
出版信息
Can Fam Physician. 2012 Sep;58(9):915.
Abstract
摘要
相似文献
1
First, do no harm.首先，不要造成伤害。
Can Fam Physician. 2012 Sep;58(9):915.
2
The dilemmas of prostate cancer screening.前列腺癌筛查的困境
Med J Aust. 2013 Jun 3;198(10):528-9. doi: 10.5694/mja13.10242.
3
Should we screen for prostate cancer? A re-examination of the evidence.我们应该筛查前列腺癌吗？对证据的重新审视。
Med J Aust. 2013 Jun 3;198(10):525-7. doi: 10.5694/mja12.11576.
4
Prostate cancer screening can save lives but it is too early for a national programme, study finds.研究发现，前列腺癌筛查可挽救生命，但开展全国性项目时机尚早。
BMJ. 2014 Aug 6;349:g5055. doi: 10.1136/bmj.g5055.
5
Baseline PSA testing for men in their 40s: currently available evidence strongly supports baseline PSA measurements in this age group.40多岁男性的基线前列腺特异性抗原（PSA）检测：现有证据有力支持对该年龄组进行基线PSA测量。
Oncology (Williston Park). 2014 Feb;28(2):154, 156.
6
Unorganized prostate-specific antigen-based screening for prostate cancer: more harm than benefit. When will we finally start to implement guidelines and risk assessment tools in clinical practice?基于无组织前列腺特异性抗原的前列腺癌筛查：弊大于利。我们最终何时才会开始在临床实践中实施指南和风险评估工具？
Eur Urol. 2015 Sep;68(3):363-4. doi: 10.1016/j.eururo.2015.02.036. Epub 2015 Mar 11.
7
US guideline may have led to drop in PSA testing among primary care physicians, studies find.研究发现，美国指南可能导致基层医疗医生进行前列腺特异抗原（PSA）检测的次数减少。
BMJ. 2015 May 28;350:h2906. doi: 10.1136/bmj.h2906.
8
The Era of Prostate-specific Antigen-based Personalized Prostate Cancer Screening Has Only Just Begun.基于前列腺特异性抗原的个性化前列腺癌筛查时代才刚刚开始。
Eur Urol. 2015 Aug;68(2):214-5. doi: 10.1016/j.eururo.2015.01.031. Epub 2015 Feb 11.
9
Managing localized prostate cancer in the era of prostate-specific antigen screening.在前列腺特异性抗原筛查时代管理局限性前列腺癌。
Cancer. 2013 Nov 15;119(22):3906-9. doi: 10.1002/cncr.28301. Epub 2013 Sep 4.
10
Re: Improving the Specificity of Screening for Lethal Prostate Cancer Using Prostate-Specific Antigen and a Panel of Kallikrein Markers: A Nested Case-Control Study.回复：使用前列腺特异性抗原和一组激肽释放酶标志物提高致命性前列腺癌筛查特异性：一项巢式病例对照研究。
J Urol. 2015 Aug;194(2):393-4. doi: 10.1016/j.juro.2015.05.066. Epub 2015 May 18.
本文引用的文献
1
Exploring patient perceptions of PSA screening for prostate cancer: risks, effectiveness, and importance.探讨患者对前列腺癌 PSA 筛查的看法：风险、效果和重要性。
Can Fam Physician. 2012 Sep;58(9):e502-7.
2
Prostate-cancer screening--what the U.S. Preventive Services Task Force left out.前列腺癌筛查——美国预防服务工作组遗漏了什么。
N Engl J Med. 2011 Nov 24;365(21):1949-51. doi: 10.1056/NEJMp1112191. Epub 2011 Oct 26.
3
One man at a time--resolving the PSA controversy.一次关注一个人——解决前列腺特异性抗原争议。
N Engl J Med. 2011 Nov 24;365(21):1951-3. doi: 10.1056/NEJMp1111894. Epub 2011 Oct 26.
4
Screening and prostate-cancer mortality in a randomized European study.一项欧洲随机研究中的筛查与前列腺癌死亡率
N Engl J Med. 2009 Mar 26;360(13):1320-8. doi: 10.1056/NEJMoa0810084. Epub 2009 Mar 18.
5
Mortality results from a randomized prostate-cancer screening trial.一项前列腺癌随机筛查试验的死亡率结果。
N Engl J Med. 2009 Mar 26;360(13):1310-9. doi: 10.1056/NEJMoa0810696. Epub 2009 Mar 18.
Zotero 插件